Clearmind Medicine Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsClearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapies for alcohol use disorder and other addictions.
What they do
Clearmind is a biopharmaceutical company developing proprietary compounds for the treatment of alcohol use disorder (AUD) and other addictions. Its lead candidate is a patent-protected psychedelic molecule targeting central nervous system pathways. The company operates as a holding entity with wholly-owned subsidiaries in Israel (Clearmindmed Ltd.) and Canada (Clearmind Labs Corp.).
Revenue drivers
- No commercial products — The company has no approved products or commercial revenue; it is entirely preclinical/clinical stage.
Recent performance
For the fiscal year ended October 31, 2025, the company reported no revenue from operations. Net loss and cash burn are not disclosed in the provided excerpts. The company effected a 1-for-40 reverse share consolidation on December 15, 2025, reducing common shares outstanding from 1,499,838 to 158,076 as of January 19, 2026.
Strategy
Clearmind is advancing its lead drug candidate through preclinical and clinical development for alcohol use disorder. It prioritizes securing intellectual property protections, including patents. The company also maintains corporate structures in Israel and Canada to support its research and development activities.
Risks
- Clinical-stage risk — No product has received regulatory approval, and failure in clinical trials could cause the company to lose its entire investment.
- Reverse share consolidation risk — The 1-for-40 consolidation may reduce liquidity and could lead to delisting if the share price fails to meet Nasdaq minimums.
- Going concern risk — As a development-stage company with no revenue, it relies on equity financing, which may be insufficient to fund operations.
- Regulatory risk — Psychedelic-based therapies face uncertain and evolving regulatory environments that could delay or prevent commercialization.
Outlook
Management states the company will continue to focus on research and development of its psychedelic-based drug candidates. There are no disclosed commercial timelines or revenue forecasts. The company expects to fund operations through capital raises, as it has no operating revenue.